By Stacy M. Brown, NNPA Newswire Senior National Correspondent A Phase 2/3 trial conducted by Pfizer and BioNTech revealed that the Covid-19 vaccine was safe and generated a “robust antibody response” in children ages 5 to 11.These are the first such results released for this age group for a US Covid-19 vaccine. Pfizer said it […]
The post Pfizer Vaccine for Children 5 to 11 is Safe with Robust Antibody Response appeared first on Voice and Viewpoint.
